FAQ Library

FAQ Library published on December 5, 2019
In this activity, Dr. Beth Faiman covers how to manage lenalidomide-related diarrhea in newly diagnosed patients with multiple myeloma.
FAQ Library published on November 22, 2019
In this activity, Dr. Faiman will review the results of a phase I/II study of azacitidine in combination with lenalidomide and dexamethasone in patients with RRMM.
FAQ Library published on November 14, 2019
Join Dr. Faiman as she discusses the results from evaluating the safety and efficacy of pomalidomide in the real-world setting with RRMM patients.
FAQ Library published on October 30, 2019
In this activity, Dr. Drake provides some key updates in the management of bone disease in mutliple myeloma over that past couple years.
FAQ Library published on October 24, 2019
Join Dr. Drake as he covers the risk of developing complications in the skeleton after a patient with multiple myeloma achieves complete remission.
FAQ Library published on May 8, 2019
Join Dr. Philip McCarthy as he explains the development of central nervous system toxicity after cytokine-release syndrome (CRS), and also whether CRS affects CAR T cells.
FAQ Library published on April 24, 2019
In this activity, Dr. Philip McCarthy discusses cytokine-release syndrome and the most common treatment approaches.
FAQ Library published on December 3, 2018
Dr. Holstein explains the risk of developing an SPM on lenalidomide maintenance vs. the benefit of maintenance in delaying progression or death from myeloma, and how to counsel patients.
FAQ Library published on November 8, 2018
Dr. Holstein reviews the impact maintenance therapy has on patient outcomes, and what factors you must consider when prescribing maintenance therapy.
FAQ Library published on October 24, 2018
Dr. Richardson provides a brief update on recent developments in CAR-T therapy in patients with multiple myeloma, and what we can see on the horizon.
Page 1 of 15
Results 1 - 10 of 145